Langley Annie, Beecker Jennifer
1 The University of Ottawa, K19 4E9, Ottawa, ON, Canada.
2 The Ottawa Hospital, Department of Medicine, K1Y 4E9, Ottawa, ON, Canada.
J Cutan Med Surg. 2018 Jul/Aug;22(4):415-421. doi: 10.1177/1203475417748886. Epub 2017 Dec 31.
Apremilast is a relatively new therapy for the treatment of moderate to severe plaque psoriasis in adults. While this medication is considered safe with a very low risk of serious side effects, a few common (≥5% of patients) mild to moderate side effects have been reported, including diarrhea, nausea, headache, and nasopharyngitis. Not addressing these symptoms may lead to medication nonadherence and unnecessary discontinuation of therapy. These side effects are often easily managed with interventions available to the practicing dermatologist, and in only rare instances will these side effects require dose adjustment or discontinuation of therapy. The purpose of this article is to review common side effects of apremilast at its approved dose of 30 mg orally twice daily (BID) and to provide clear, simple recommendations for their management in dermatological practice.
阿普米司特是一种用于治疗成人中度至重度斑块状银屑病的相对较新的疗法。虽然这种药物被认为是安全的，严重副作用风险非常低，但已报告了一些常见的（≥5%的患者）轻度至中度副作用，包括腹泻、恶心、头痛和鼻咽炎。不处理这些症状可能导致药物治疗依从性差以及不必要的治疗中断。这些副作用通常很容易通过执业皮肤科医生可用的干预措施进行管理，只有在极少数情况下，这些副作用才需要调整剂量或停止治疗。本文的目的是回顾阿普米司特批准剂量为每日口服两次30mg时的常见副作用，并为皮肤科实践中对其的管理提供清晰、简单的建议。
